Subscribe to Newsletter

Business & Regulation

Business & Regulation Standards & Regulation

RFK Jr’s Speech Leaks: Vaccines, Autism, and Chronic Illness

| Stephanie Vine | 3 min read

Robert F Kennedy Jr’s recent speech suggests that investigations into childhood vaccines and over-medication could be on the cards.

Business & Regulation Standards & Regulation

AMF’s 2026 AMR Strategy, Revealed

| Rob Coker | 3 min read

The Access to Medicine Foundation has developed the 2026 AMR Benchmark to recognize and promote urgency in the ongoing AMR challenge.

Business & Regulation Trends & Forecasts

Our Videos: The Greatest Hits

| 1 min read

From gene therapy to novel excipients to trends in leadership and more. Check out some of our most popular videos.

Business & Regulation Business Practice

GenAI: Automating Regulatory Submissions

| Agnes Cwienczek | 4 min read

Within two years, pharma companies may be able to rely on technology to automatically create and cross-check entire regulatory submissions.

Business & Regulation Standards & Regulation

Researchers Respond to NIH Funding Cuts

| Stephanie Vine | 4 min read

Stakeholders explain why the NIH’s move to cap indirect costs associated with research grants could damage medical innovation.

Business & Regulation Contract Manufacturing Services

The Secret to Being a Good Employer

| 4 min read

Why you shouldn’t neglect the importance of blending people, culture, and strategy to foster success in a business.

Business & Regulation Standards & Regulation

Trump’s Tariffs

| Rob Coker | 3 min read

US-based pharmaceutical associations fear the supply chain repercussions of tariffs, and offer advice for a more sustainable alternative.

Business & Regulation Bioprocessing - Upstream & Downstream

Sanofi’s Push for Pricing Flexibility in the UK

| 6 min read

We speak with Sanofi’s Anju Bhalla about its appeal against NICE’s final draft guidance for Sarclisa.

Business & Regulation Standards & Regulation

Robert F. Kennedy Jr Nomination Advances

| Stephanie Vine | 2 min read

Senate committee votes in favor of the nomination; full Senate vote will be next.

Business & Regulation Profession

Maintaining Momentum

| 4 min read

Being part of the cell and gene therapy field is an incredible privilege, according to Frank Mathias, CEO, Oxford Biomedica.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register